U.S. consumer watchdog Public Citizen on Thursday excoriated Pfizer after the pharmaceutical giant announced it would more than double the price of a lifesaving Covid-19 treatment, which will soon sell for an estimated 100 times the cost of production.

Pfizer said Wednesday that it will price its patented Covid treatment nirmatrelvir-ritonavir—sold under the brand name Paxlovid—at $1,390 for a five-day course. Researchers Melissa J. Barber and Dzintars Gotham recently estimated it costs Pfizer $13 to produce five days’ worth of the drug, which is taken in three-pill doses.

“Pfizer’s new price is an estimated 100 times the cost of production,” Peter Maybarduk, director of Public Citizen’s Access to Medicines program, said in a statement.

It’s also more than 2.5 times the federal government’s purchase price for Paxlovid. The government has bought and distributed the antiviral drug to the public free of charge since December 2021, when the U.S. Food and Drug Administration approved the treatment. Starting next year, Pfizer will sell Paxlovid directly to health insurance companies.

“Pfizer has made tens of billions in Paxlovid sales, largely through major government purchases,” Maybarduk noted. “Pfizer could choose now to support the fight against Covid and ease treatment access by lowering its already inflated prices.”

“Instead, Pfizer chose to double its U.S. price just as pandemic funding falters and the precarious winter viral season begins,” he continued. “This will strain health budgets and contribute to further treatment rationing.”

“Pfizer treats Paxlovid like a Prada handbag; a luxury for the few rather than a treatment for the many,” Maybarduk added. “For shame.”

Medical professionals and patient advocates have voiced concerns that increasing the price of Paxlovid could leave at-risk people without access to the lifesaving drug, which is proven to reduce the risk of death or severe illness from Covid-19 for patients with weakened immune systems or ailments like diabetes and heart conditions.

News of the Paxlovid price hike came a day after Public Citizen and the Health Global Access Project (Health GAP) published an analysis revealing that more than 8 million people with high-risk Covid-19 infections in low- and middle-income nations could not access the drug last year, leaving over 90% of the need for the treatment unmet.

“At a minimum, 10 times more people needed Paxlovid than had any chance to receive it in developing countries, and that almost certainly significantly understates the problem,” Maybarduk said on Tuesday.

In addition to Paxlovid, Pfizer manufactures one of the two available mRNA vaccines for Covid-19. The company reported $56 billion in sales of its Covid-19 vaccine and Paxlovid last year. However, projecting a sales slump in 2023, Pfizer late last year announced a plan to significantly hike the price of its publicly funded Covid-19 shot.

Pfizer reported profits of $31.4 billion in 2022, a 43% increase over the previous year. Pfizer CEO Albert Bourla took home $33 million in compensation last year, a 36% raise from 2021.

Your support matters…

Independent journalism is under threat and overshadowed by heavily funded mainstream media.

You can help level the playing field. Become a member.

Your tax-deductible contribution keeps us digging beneath the headlines to give you thought-provoking, investigative reporting and analysis that unearths what's really happening- without compromise.

Give today to support our courageous, independent journalists.